X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents including AST-008 (cavrotolimod), an SNA consisting of toll-like receptor 9 agonists designed for immuno-oncology applications.
Lead Product(s): Cavrotolimod
Therapeutic Area: Infections and Infectious Diseases Product Name: AST-008
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bluejay
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 05, 2024
Details:
SNAs are nanoscale constructs consisting of synthetic nucleic acid sequences densely radiating from a spherical core. SNA-based Therapeutic gives rise to distinct chemical and biological properties and may provide advantages over other nucleic acid therapeutics.
Lead Product(s): SNA-based Therapeutic
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $1,045.0 million Upfront Cash: $45.0 million
Deal Type: Termination December 14, 2022
Details:
SNAs are nanoscale constructs consisting of synthetic nucleic acid sequences densely radiating from a spherical core. SNA-based Therapeutic gives rise to distinct chemical and biological properties and may provide advantages over other nucleic acid therapeutics.
Lead Product(s): SNA-based Therapeutic
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Ipsen
Deal Size: $1,020.0 million Upfront Cash: $20.0 million
Deal Type: Termination December 14, 2022
Details:
Cavrotolimod (AST-008) is an SNA consisting of toll-like receptor 9 agonists designed for immuno-oncology applications. Cavrotolimod is in a Phase 1b/2 clinical trial in patients with advanced solid tumors.
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2021
Details:
Under the agreement, Ipsen will receive exclusive options to license SNA-based therapeutics arising from two collaboration programs for Huntington’s disease and Angelman syndrome.
Lead Product(s): SNA-based Therapeutics
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Ipsen
Deal Size: $1,020.0 million Upfront Cash: $20.0 million
Deal Type: Collaboration August 02, 2021
Details:
Cavrotolimod (AST-008) is an SNA consisting of toll-like receptor 9 agonists designed for immuno-oncology applications. The U.S. FDA has granted Orphan Drug Designation for cavrotolimod (AST-008), for the treatment of patients with Merkel cell carcinoma (MCC).
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2021
Details:
The fast track designations for cavrotolimod has been granted for two development programs: cavrotolimod in combination with anti-PD-1 therapy for metastatic Merkel cell carcinoma and cavrotolimod in combination with anti-PD-(L)1) therapy in cutaneous squamous cell carcinoma.
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2021
Details:
Updated data from the Phase 1b stage demonstrated that the combination of cavrotolimod and pembrolizumab continued to be well tolerated, with a confirmed overall response rate (ORR) of 21% (4/19 patients) according to RECIST v1.1 criteria.
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Cavrotolimod, the company’s SNA-enabled TLR9 agonist, is being developed for the treatment of solid tumors, in combination with anti-programmed cell death 1 (PD-1) therapy.
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
The cavrotolimod pharmacodynamic profile corroborated the efficacy data, as increased serum cytokines/chemokines, activated immune cells, and tumor infiltration by immune cells were observed.
Lead Product(s): Cavrotolimod,Pembrolizumab
Therapeutic Area: Oncology Product Name: AST-008
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
